The Changing Face of Clostridium difficile: What Treatment Options Remain?

Shen, Edie P.; Christina, M. Surawicz
December 2007
American Journal of Gastroenterology;Dec2007, Vol. 102 Issue 12, p2789
Academic Journal
In this issue of the Journal, an article by Pepin et al. documents the shifting sands of the modern-day Clostridium difficile epidemic as seen in Quebec. Pepin and coauthors' observation that the superior activity of vancomycin over metronidazole has been lost since the emergence there of the hypervirulent strain NAP1/027 in 2003 has implications for the future treatment of C. difficile-associated diarrhea (CDAD). This editorial explores these, particularly in complicated cases and high-risk populations.


Related Articles

  • Vancomycin better first-line choice for severe C. diff.  // Hospital Infection Control;Feb2007, Vol. 34 Issue 2, p15 

    The article discusses research being done on vancomycin as a treatment of severe Clostridium difficile-associated diarrhea. It references a study by Fred A Zar, et al, presented at a conference by the Infectious Disease Society of America in October 2006 in Toronto. According to the study,...

  • Antimicrobial susceptibilities of Clostridium difficile isolated in Japan. Kunishima, Hiroyuki; Chiba, Junichi; Saito, Michiko; Honda, Yoshihiro; Kaku, Mitsuo // Journal of Infection & Chemotherapy;Apr2013, Vol. 19 Issue 2, p360 

    Clostridium difficile is a common causative organism of antimicrobial-associated diarrhea and is often responsible for nosocomial infection. C. difficile infection has traditionally been treated with metronidazole (MNZ) or vancomycin (VCM); however, MNZ-resistant strains have reported in some...

  • The Evolution of Urban C. difficile Infection (CDI): CDI in 2009-2011 Is Less Severe and has Better Outcomes Than CDI in 2006-2008. Feuerstadt, Paul; Das, Rohit; Brandt, Lawrence J // American Journal of Gastroenterology;Aug2014, Vol. 109 Issue 8, p1265 

    OBJECTIVES:Over the past decade, the epidemiology of Clostridium difficile infection (CDI) has shown a remarkable increase in incidence with an associated increase in severity. This study was designed to compare the demographics, medication exposure, evaluation, treatment patterns, and outcomes...

  • Markers of Intestinal Inflammation, Not Bacterial Burden, Correlate With Clinical Outcomes in Clostridium difficile Infection. El Feghaly, Rana E.; Stauber, Jennifer L.; Deych, Elena; Gonzalez, Carlos; Tarr, Phillip I.; Haslam, David B. // Clinical Infectious Diseases;Jun2013, Vol. 56 Issue 12, p1713 

    Fecal inflammatory markers at diagnosis correlate with diarrhea persistence and treatment failure in Clostridium difficile infection, whereas C. difficile fecal bacterial burden does not. C. difficile bacterial concentration decreases similarly in patients treated with metronidazole and...

  • Clostridium difficile associated diarrhoea: diagnosis and treatment. Starr, John // BMJ: British Medical Journal (International Edition);9/3/2005, Vol. 331 Issue 7515, p498 

    Discusses Clostridium difficile associated diarrhea, which has been linked to third generation cephalosporins. Symptoms and transmission of C difficile; Risk factors for colonization and toxin production; Effectiveness of oral metronidazole and vancomycin treatments; The use of probiotics in...

  • Caviar Among the Ruins. Gaby, Alan R. // Townsend Letter;May2010, Issue 322, p124 

    The author comments on a study which assessed the effects of monoclonal antibodies on the recurrence rate of Clostridium difficile infection, published in the January 21, 2010 issue of the "New England Journal of Medicine." He states that the infection is caused by a bacterium that is usually...

  • Pathogenesis and treatment of Clostridium difficile infection. Tonna, I.; Welsby, P. D. // Postgraduate Medical Journal;Jun2005, Vol. 81 Issue 956, p367 

    This article focuses on the pathogenesis and treatment of Clostridium difficile (CD) infection. CD is a gram positive, spore forming anaerobic bacillus that in contrast with popular belief is not a normal commensal of the adult gastrointestinal tract. There are two prerequisites for developing...

  • Fidaxomicin inhibits toxin production in Clostridium difficile. Babakhani, Farah; Bouillaut, Laurent; Sears, Pamela; Sims, Carlee; Gomez, Abraham; Sonenshein, Abraham L. // Journal of Antimicrobial Chemotherapy (JAC);Mar2013, Vol. 68 Issue 3, p515 

    Objectives Fidaxomicin, which was recently approved for the treatment of Clostridium difficile-associated diarrhoea, demonstrates narrow-spectrum bactericidal activity via inhibition of RNA polymerase. In this study we evaluated its inhibitory activity versus C. difficile toxin gene expression...

  • Narrative Review: The New Epidemic of Clostridium difficile-- Associated Enteric Disease. Bartlett, John G. // Annals of Internal Medicine;11/21/2006, Vol. 145 Issue 10, p758 

    Antibiotic-associated diarrhea and colitis were well established soon after antibiotics became available. Early work implicated Staphylococcus aureus, but in 1978 Clostridium difficile became the established pathogen in the vast majority of cases. In the first 5 years (1978 through 1983), the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics